Sim&Cure has raised $11,652,251 in investment capital. Founded in 2014 in Montpellier, France, the digital health start-up specializes in leveraging Digital Twin and AI Technologies to improve patient outcomes and physician experience in endovascular treatments. The company's core philosophy centers on driving innovation within the healthcare industry and enhancing treatment strategies to secure patient care, while also assisting partners in flattening the learning curve for new medical technologies.
This significant funding round underscores investor confidence in Sim&Cure's pioneering approach. The company has previously been recognized for its innovation, winning the i-Lab national contest twice in 2014 and 2015, and i-Nov in 2020. Sim&Cure is backed by the Seed Fund IT-Translation and Elaia Partners, and has established scientific and clinical collaborations with leading laboratories and hospitals worldwide, further validating its expertise and global ambition.
The newly secured capital will be strategically deployed to accelerate Sim&Cure's growth initiatives. With a current team of 50 employees and a subsidiary opened in New York in July 2019, the company anticipates a phase of strong expansion. The investment will support the scaling of its technology platform and the broadening of its market presence.
This funding positions Sim&Cure to solidify its leadership in the Medtech ecosystem. The company is committed to advancing its mission of transforming endovascular treatment through digital innovation, ensuring improved patient care and physician efficiency on a global scale.
.png&w=3840&q=75)
